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Introduction
Many pathogens exhibit high mutation rates, generating new genetic variants that 
are resistant to an existing immune response to earlier pathogen subtypes (Mendis 
et al. 1991; Phillips et al. 1991; Weber and Elliott 2002), difficulting the task of 
vaccine development. It is therefore important to focus on conserved regions during 
the process of vaccine design.
Several research groups have tried to develop vaccines based on quimeric consensus 
sequences (Thomsona et al. 2005). However, these vaccines have a major disadvan-
tage as chimeric consensus proteins still bear nonconserved connecting regions, 
which might be more inmunogenic than conserved ones and thus truncate the devel-
opment of a protective immune response. Nonprotective immunodominance can 
however be overcome using antigenic determinants (epitopes) as vaccines, as one can 
drive the immune response only towards the conserved epitopes of interest (Sette 
et al. 2002; Tsuji and Zavala 2001; Disis et al. 2001; Reche et al. 2006).
The estimation of sequence variability from MSAs of protein antigens also pro-
vides a means to identify conserved antigenic determinants. In this chapter, we will 
illustrate the use of PVS (García-Boronat et al. 2008), a Protein Variability Server 
that has been tuned to facilitate the discovery of conserved epitopes. Specifically, 
we will use PVS to obtain the conserved regions of the HIV-1 gp120 and gp41 
proteins, identifying those that are solvent exposed, and therefore, likely the targets 
of cross-neutralizing antibodies (Abs). Likewise, we will use PVS to generate a 
variability-masked sequence of the HIV-1 gp120 protein, which will be targeted for 
T cell epitope predictions. Epitope-vaccine development requires confirming the 
immunogenicity of vaccine candidates, which consumes a vast amount of time and 
resources. Interestingly, sequence variability analyses in PVS dramatically reduce 
the number of potential epitope-vaccine candidates one would need to consider. 
PVS is freely available at the site http://imed.med.ucm.es/PVS.
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Materials and Methods
MSAs
For this study two proteins are used: The gp120 (residues 31-183 in gp160) and the 
gp41 (residues 528–674 in gp160), which are both membrane glycoproteins of 
HIV-1 (strain H2XB2). Both the gp120 and gp41 MSAs, were generated from 359 
representative sequences of the HIV-1 clades A (73), B (85), C (85), D (51) and 
01_AE (65) using the program MUSCLE (Edgar 2004). The gp41 and gp120 
MSAs are available at http://imed.med.ucm.es/PVS/supplemental/gp120_pvs.html 
and http://imed.med.ucm.es/PVS/supplemental/gp41_pvs.html, respectively.
PVS Description and Usage
PVS (Protein Variability Server) is a web-based tool (Fig. 1) that following a protein 
sequence variability analysis performs several tasks that are relevant for structure-
Fig. 1 PVS web interface. The web interface is divided into the INPUT, SEQUENCE 
VARIABILITY OPTIONS and OUTPUT TASKS sections which overall facilitate an intuitive use of 
the server. The web interface also provides links to help pages and specific information regarding 
the elements featured by the server accessible from the question mark icons
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function studies and vaccine design. PVS main input is an MSA provided by the user, 
but it can also take a PDB file as main input, generating an MSA from it (for details 
see García-Boronat et al. 2008) The sequence variability in the MSA is computed 
per site using three different metrics: The Shannon Diversity index (Shannon 
Entropy) (Shannon 1948), the Simpson Diversity Index (Simpson 1949) and the 
Wu-Kabat Variability Coefficient (Wu and Kabat 1970). In this study, we have 
selected the Shannon Diversity Index (H) as the variability metric. H ranges from 0 
(only one amino acid type is present at that position) to 4.322 (all 20 amino acids 
are equally represented in that position). Note, that for a site including gaps the 
maximum value of H will be 4.39. A site with a value of H under 1.0 is indicative of 
a site with very low variability (Reche and Reinherz 2003).
PVS optional tasks include that of plotting the variability in MSA – computed 
for each selected variability method – against a sequence consisting of a con-
sensus sequence or the first sequence in the MSA. If the task “map structure 
variability” is selected and a PDB with relevant 3D-coordinates is submitted, 
PVS will map the sequence variability in the MSA onto the provided 3D-structure. 
Mapping the sequence variability onto the provided PDB is achieved by simply 
replacing the B-factor of the relevant residues with the variability values. Variability 
mapped 3D-structures can be visualized and manipulated interactively using 
JMOL (http://jmol.sourceforge.net/). The variability is shown in the 3D-structrure 
using a color scale that goes from blue for constant residues to red for highly variable 
residues. PVS also offers the possibility of returning the “conserved fragments.” 
A variability threshold (Vt) and a minimum length of the conserved fragments 
need to be provided with this option. Under these selections, if a PDB is provided, 
PVS will also display a graph of the protein sequence with the conserved frag-
ments shown in blue. By clicking on a fragment, one can locate the fragment on 
the 3D structure.
Finally, PVS can return the selected reference sequence with the variable positions 
masked. Specifically, those residues with variability greater than a user selected 
threshold will be shown with a “.” symbol. The returned masked sequence is in 
FASTA format and can be directly submitted to RANKPEP (Reche and Reinherz 
2007; Reche et al. 2004; Reche et al. 2002), a T cell epitope prediction tool that can 
anticipate conserved T-cell epitopes from a variability-masked sequence.
Results and Conclusion
Sequence variability is exploited by biological systems to generate functional 
heterogeneity (e.g., receptors involved in antigen recognition). Therefore, sequence 
variability analyses have traditionally been used to fill gaps in structural knowledge 
(Wu and Kabat 1970; Reche and Reinherz 2003). In addition, sequence variability 
analyses are also important for vaccine development as they also enable the identi-
fication of conserved antigenic determinants (Reche et al. 2006). For that purpose, 
we recently developed PVS, a web-based tool for protein variability analysis, 
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Fig. 2 PVS and T cell epitope predictions. (a) Variability-masked sequence. The shown sequence 
obtained from an MSA of HIV-1 gp120 (consensus sequence was selected as the reference 
sequence). The sequence is in FASTA format and positions indicated by dots, “.”, display a 
variability > 1.0. (b) Rankpep web interface. By clicking on the button “Run Epitope Predictions” 
one will directly submit this sequence for conserved T cell epitope predictions using the 
RANKPEP algorithm. (c) RANKPEP results for the variability-masked sequence of the gp120. 
Only fragments KLTPLCUTL and PVVSTQLLL were predicted to have a binding score above 
the threshold
99Discovery of Conserved Epitopes Through Sequence Variability Analyses
BookID 141320_ChapID 8_Proof# 1 - 02/09/2009
which implements several features that are thought to facilitate epitope-vaccine 
design. Next we will discuss such features using HIV-1 as the pathogenic model.
PVS can be used to facilitate the identification of conserved T cell epitopes. 
As an example we used an MSA from the HIV-1 gp120 protein (see Sect. 1 for 
details) to first obtain a variability masked sequence (Fig. 2a), which was subse-
quently targeted for the prediction of CD8+ T cell epitopes restricted by the HLA I 
molecule A*0201 (Fig. 2b). Interestingly, only two T cell epitopes (KLTPLCVTL 
and PVVSTQLLL) were predicted to have a binding score above the threshold 
(Fig. 2c) In comparison, the complete gp120 sequence (strain H2XB2) would yield 
10 different epitopes. Thus, regardless of the predictive power of RANKPEP, this 
strategy saves the time, effort and resources that one will need to confirm non-
conserved T cell epitopes that are not as suitable for epitope-vaccine design.
PVS results can also be useful for the identification of conserved B cell epitopes, 
the antigenic determinants of Abs. For example, the ectodomain of HIV-1 gp41 is 
known to be the target of various broadly neutralizing Abs (Zolla-Pazner 2004). 
When PVS is run with an MSA of this protein, 7 highly conserved fragments of 6 
of more residues are returned (Table 1). Interestingly, fragments WGCSGK and 
WLWYIK encompass the antigenic determinants of the monoclonal Abs CL3 and 
ZE10, both broadly neutralizing. As we can see, the targets of broadly neutralizing 
Abs lie within conserved fragments.
Abs only recognize solvent-exposed epitopes, and most of them are conformational 
–although, some can also be linear–. To help identifying solvent-exposed fragments, 
PVS also allows exploring the location of the conserved fragments in the 3D-structure 
of the protein (when available). The use of such solvent-exposed conserved frag-
ments as immunogens greatly increases the chance of raising Abs that are both, 
crossreactive with the native antigen and broadly neutralizing. For example, Table 2 
shows that there are only eight highly conserved fragments lying within the 
reported gp120 structure (PDB 1RZK, chain G).
However, by mapping the conserved gp120 fragments onto the 3D-structure 
(Fig. 3) one could see that only fragment 2 and fragment 3 and significant portions of 
fragments 1, 4 and 6 are accessible to the solvent. Therefore, these solvent-exposed 
Table 1 Conserved fragments in the ectodomain of HIV-1 gp41 calculated by PVS
N Start End Sequence
1 1 7 S T M G A A S
2 9 25 T L T V Q A R Q L L S G I V Q Q Q
3 27 55 N L L R A I E A Q Q H L L Q L T V W G I K Q L Q A R V L A
4 62 67 D Q Q L L G
5 69 74 W G C S G K
6 87 92 S W S N K S
7 153 158 W L W Y I K
Fragments were selected to have six or more consecutive residues with H ? 1, and were 
obtained form an MSA of the HIV-1 gp41 ectodomain
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fragments are the only peptides from HIV-1 gp120 that may elicit both cross-
neutralizing cross-reactive Abs with the native gp120.
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Table 2 Conserved fragments of the HIV-1 glycoprotein gp120 calculated by PVS
N Start End Sequence
1 22 44 D I I S L W D Q S L K P C V K L T P L C V T L
2 52 61 I T Q A C P K V S F
3 63 73 P I P I H Y C A P A G
4 93 119 N V S T V Q C T H G I K P V V S T Q L L L N G S L A E
5 202 209 G E F F Y C N T
6 232 242 C R I K Q I I N M W Q
7 261 273 S N I T G L L L T R D G G
8 289 303 M R D N W R S E L Y K Y K V V
Fragments were selected to have eight or more consecutive residues with H ? 1, and were obtained 
from an MSA of HIV-1 gp120 (See Material and Methods). The “Map structure variability” task 
was selected and chain G of PDB 1RZK containing the 3D-coordinates of HIV-1 gp120 was 
entered in the server. Relevant sequence in PDB is considerably shorter than that of MSA, and 
only those fragments mapping within the PDB sequence are reported by the server
Fig. 3 Exploring solvent accessibility of conserved fragments. Arrow shows the location of 
fragment 2 (ITQACPKVSF) in the 3D-structure of gp120 (chain G of PDB 1RZK). It was 
located on the 3D-structure by simply clicking on the corresponding fragment shown under the 
linear representation of gp120
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